Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Akari Therapeutics (NQ: AKTX)
2.100 USD  -0.040 (-1.87%)
Streaming Delayed Price  /  Updated: 11:51 AM EDT, Jun 24, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 26,628
Open 2.130
Bid (Size) 2.070 (3)
Ask (Size) 2.110 (7)
Prev. Close 2.140
Today's Range 2.010 - 2.130
52wk Range 1.560 - 9.200
Shares Outstanding 15,256,933
Dividend Yield N/A
Performance
YTD
+26.13%
+26.13%
1 Month
-8.70%
-8.70%
3 Month
-43.09%
-43.09%
6 Month
+19.32%
+19.32%
1 Year
-4.55%
-4.55%
Top News
More News
Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene... Read More
from GlobeNewswire News Releases
Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems... Read More
from GlobeNewswire News Releases
More News
Read More
Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
from GlobeNewswire News Releases
Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
from GlobeNewswire News Releases
Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid
from GlobeNewswire News Releases
Recent Analysis Shows Extra Space Storage, OPKO Health, El Pollo Loco, Willis Towers Watson Public, Molina Healthcare, and Akari Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
from GlobeNewswire News Releases
Akari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation
category Biotech , Nomacopan , News , and 4 more.
from Benzinga
Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
from GlobeNewswire News Releases
Thinking about buying stock in Aurora Cannabis Inc., Akari Therapeutics, Atossa Genetics Inc., Boeing Co., or Reebonz Holding Ltd.?
from PR Newswire
Mid-Afternoon Market Update: Dow Rises Over 100 Points; Akari Therapeutics Shares Spike Higher
category EIDX , TWTR , MBRX , and 17 more.
from Benzinga
Mid-Day Market Update: Hasbro Rises After Q1 Results; Emerge Energy Services Shares Slide
category Paper Products , IMUX , Mid/Day Market Update , and 19 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.